Cargando…

Triple Negative Breast Cancer at the University Hospital Mohammed VI – Oujda

INTRODUCTION: The triple-negative breast cancer (TNBC), defined by the absence of receptors to oestrogen and progesterone and no histochemical expression of human epidermal receptor -2, is associated with a particularly aggressive behavior. The aim of our study was to determine the clinico-pathologi...

Descripción completa

Detalles Bibliográficos
Autores principales: Al jarroudi, O, Abda, N, Brahmi, SA, Afqir, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5563100/
https://www.ncbi.nlm.nih.gov/pubmed/28240519
http://dx.doi.org/10.22034/APJCP.2017.18.1.195
_version_ 1783258075442970624
author Al jarroudi, O
Abda, N
Brahmi, SA
Afqir, S
author_facet Al jarroudi, O
Abda, N
Brahmi, SA
Afqir, S
author_sort Al jarroudi, O
collection PubMed
description INTRODUCTION: The triple-negative breast cancer (TNBC), defined by the absence of receptors to oestrogen and progesterone and no histochemical expression of human epidermal receptor -2, is associated with a particularly aggressive behavior. The aim of our study was to determine the clinico-pathological, therapeutic and prognostic features associated with this type of breast cancer in Morocco. METHODS: A cohort retrospective study, spread over 3 years, was conducted of 116 breast cancer patients, diagnosed between January 2009 and December 2011 at the Regional Center of Oncology. Epidemiological, clinical, histological and therapeutic data were analyzed. Survival curves at 3 years were estimated by Kaplan-Meier analysis with use of the log-rank test. RESULTS: The proportion of triple-negative breast cancer in our series was 13.2%. The average age was 46.5 years and 20,7% had a previous history of familial breast cancer. Some 56,9% of tumors were greater than 3 cm in diameter. infiltrating ductal carcinoma being the histological type in the majority of cases (75.9%). TNBC was most often associated with a high grade, grade III accounting for 50.9%. Vascular invasion was found in 58.6% of cases. Regarding lymph node involvement, 42.2% had positive lymph nodes and 15.5% featured distant metastases. Neoadjuvant chemotherapy was administrated to 20% of patients with a 23.5% complete pathologic response. The rates for overall survival and disease-free-survival at 3 years for localized stages were 70 and 55.6%, respectively. With metastatic lesions, the figures were 27.5% and 10.3% respectively. CONCLUSION: The TNBC is correlated with a poor prognosis with a high mortality and early relapse requiring identification of new target therapies and markers for prediction of tumoral response to various treatments.
format Online
Article
Text
id pubmed-5563100
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-55631002017-08-28 Triple Negative Breast Cancer at the University Hospital Mohammed VI – Oujda Al jarroudi, O Abda, N Brahmi, SA Afqir, S Asian Pac J Cancer Prev Research Article INTRODUCTION: The triple-negative breast cancer (TNBC), defined by the absence of receptors to oestrogen and progesterone and no histochemical expression of human epidermal receptor -2, is associated with a particularly aggressive behavior. The aim of our study was to determine the clinico-pathological, therapeutic and prognostic features associated with this type of breast cancer in Morocco. METHODS: A cohort retrospective study, spread over 3 years, was conducted of 116 breast cancer patients, diagnosed between January 2009 and December 2011 at the Regional Center of Oncology. Epidemiological, clinical, histological and therapeutic data were analyzed. Survival curves at 3 years were estimated by Kaplan-Meier analysis with use of the log-rank test. RESULTS: The proportion of triple-negative breast cancer in our series was 13.2%. The average age was 46.5 years and 20,7% had a previous history of familial breast cancer. Some 56,9% of tumors were greater than 3 cm in diameter. infiltrating ductal carcinoma being the histological type in the majority of cases (75.9%). TNBC was most often associated with a high grade, grade III accounting for 50.9%. Vascular invasion was found in 58.6% of cases. Regarding lymph node involvement, 42.2% had positive lymph nodes and 15.5% featured distant metastases. Neoadjuvant chemotherapy was administrated to 20% of patients with a 23.5% complete pathologic response. The rates for overall survival and disease-free-survival at 3 years for localized stages were 70 and 55.6%, respectively. With metastatic lesions, the figures were 27.5% and 10.3% respectively. CONCLUSION: The TNBC is correlated with a poor prognosis with a high mortality and early relapse requiring identification of new target therapies and markers for prediction of tumoral response to various treatments. West Asia Organization for Cancer Prevention 2017 /pmc/articles/PMC5563100/ /pubmed/28240519 http://dx.doi.org/10.22034/APJCP.2017.18.1.195 Text en Copyright: © Asian Pacific Journal of Cancer Prevention http://creativecommons.org/licenses/BY-SA/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
spellingShingle Research Article
Al jarroudi, O
Abda, N
Brahmi, SA
Afqir, S
Triple Negative Breast Cancer at the University Hospital Mohammed VI – Oujda
title Triple Negative Breast Cancer at the University Hospital Mohammed VI – Oujda
title_full Triple Negative Breast Cancer at the University Hospital Mohammed VI – Oujda
title_fullStr Triple Negative Breast Cancer at the University Hospital Mohammed VI – Oujda
title_full_unstemmed Triple Negative Breast Cancer at the University Hospital Mohammed VI – Oujda
title_short Triple Negative Breast Cancer at the University Hospital Mohammed VI – Oujda
title_sort triple negative breast cancer at the university hospital mohammed vi – oujda
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5563100/
https://www.ncbi.nlm.nih.gov/pubmed/28240519
http://dx.doi.org/10.22034/APJCP.2017.18.1.195
work_keys_str_mv AT aljarroudio triplenegativebreastcancerattheuniversityhospitalmohammedvioujda
AT abdan triplenegativebreastcancerattheuniversityhospitalmohammedvioujda
AT brahmisa triplenegativebreastcancerattheuniversityhospitalmohammedvioujda
AT afqirs triplenegativebreastcancerattheuniversityhospitalmohammedvioujda